SPRAVATO® news topic
Treatment updates
Every update we have published on treatment updates, newest first. Each report names the primary source so you can check it yourself.
September 28, 2026
What the Pivotal Esketamine Trials Showed — and What They Didn't
The TRANSFORM, SUSTAIN, and ASPIRE studies established SPRAVATO®'s approvals. Here is what the evidence supports — and where it stops.
September 28, 2026
FDA Label Now Allows SPRAVATO® Alone for Treatment-Resistant Depression
The January 2025 prescribing information lists SPRAVATO® for adult TRD either as monotherapy or with an oral antidepressant.
Primary source: U.S. Food and Drug Administration